1.615

0.64% -0.005

Opko Health Inc (OPK)

Overview News Price History Option Chain Financials Why OPK Down? Discussions Forecast

Opko Health Inc stock is traded at $1.615, with a volume of 891.41K. It is down -0.64% in the last 24 hours and up +6.60% over the past month. OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.

Previous Close:

$1.62

Open:

$1.62

24h Volume:

891.41K

Relative Volume:

0.23

Market Cap:

$1.09B

Revenue:

$711.41M

Net Income/Loss:

$-133.73M

P/E Ratio:

-8.50

EPS:

-0.19

Net Cash Flow:

$-199.99M

1W Performance:

+5.90%

1M Performance:

+6.60%

6M Performance:

+25.76%

1Y Performance:

+60.97%

1-Day Range:

$1.59

$1.639

1-Week Range:

$1.47

$1.66

52-Week Range:

$0.8601

$1.76

Opko Health Inc Stock (OPK) Company Profile

Name

Opko Health Inc

Sector

Healthcare (1187)

Industry

Diagnostics & Research (60)

Phone

305-575-4181

Address

4400 BISCAYNE BLVD., MIAMI, FL

Employee

3,930

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

OPK's Discussions on Twitter

Compare OPK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OPK Opko Health Inc	1.615	1.09B	711.41M	-133.73M	-199.99M	-0.19
TMO Thermo Fisher Scientific Inc	572.23	219.06B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	207.69	151.02B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	145.85	42.12B	6.51B	1.29B	1.37B	4.42
IDXX Idexx Laboratories Inc	459.04	37.71B	3.84B	866.24M	792.60M	10.37
IQV Iqvia Holdings Inc	208.18	36.97B	15.32B	1.41B	1.96B	7.62

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy
Nov-25-19	Initiated	Piper Jaffray	Overweight
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy
Jun-03-16	Initiated	Standpoint Research	Buy
Mar-31-16	Reiterated	Barrington Research	Outperform
Oct-16-15	Initiated	JP Morgan	Overweight
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform
Mar-14-14	Initiated	Oppenheimer	Outperform
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy
May-30-13	Reiterated	Ladenburg Thalmann	Buy
Oct-22-12	Initiated	Barrington Research	Outperform
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy
Jul-14-11	Initiated	Ladenburg Thalmann	Buy

View All

Opko Health Inc Stock (OPK) Latest News

Feb 06, 2025

Insiders continue to buy OPKO Health, Inc. (NASDAQ:OPK) and now own 52% shares - Simply Wall St

Feb 06, 2025

Feb 05, 2025

Y.D. More Investments Ltd Reduces Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Feb 05, 2025

Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud - Grizzly Reports

Feb 05, 2025

Feb 04, 2025

OPKO Health (NASDAQ:OPK) Sees Strong Trading VolumeShould You Buy? - MarketBeat

Feb 04, 2025

Feb 01, 2025

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 47,537 Shares - MarketBeat

Feb 01, 2025

Jan 28, 2025

Opko health CEO Phillip Frost buys $70,060 in stock By Investing.com - Investing.com Australia

Jan 28, 2025

OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Jan 24, 2025

Jan 22, 2025

Billionaire Phillip Frost's health care company settles case with federal government - The Business Journals

Jan 22, 2025

Jan 20, 2025